Emerging Therapies for Acute and Chronic Heart Failure: Hope or Hype?. (February 2016)

• Record Type: Journal Article
• Authors: Hanigan, Sarah; DiDomenico, Robert J.
• Editors: DiDomenico, Robert J.; Sanoski, Cynthia A.
• Other Names: Dobesh Paul P. guest-editor.
• Is Part Of: Journal of pharmacy practice. Volume 29:Number 1(2016:Feb.)
• Page Start: 46
• Page End: 57
• Publication Date: 2016-02
• Subjects: heart failure -- investigational drugs -- ivabradine -- LCZ696 -- serelaxin -- omecamtiv mecarbil -- ularitide; Pharmacy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1177/1933719115615877
• Languages: English
• ISSNs: 0897-1900

Abstract

Although the period from 1953 to 2001 resulted in the approval of more than 30 medications currently used to treat heart failure (HF), few novel drugs have been approved in the last decade. However, the investigational pipeline for HF medications once again appears promising. In patients with chronic heart failure with reduced ejection fraction (HFrEF), ivabradine and valsartan/sucubitril (LCZ696) were recently approved by the US Food and Drug Administration. Both agents have been shown to reduce the risk of cardiovascular death and HF hospitalization. In the treatment of acute HF, serelaxin and ularitide are the farthest along in development. Both agents have demonstrated favorable effects on surrogate end points and preliminary data suggest a possible mortality benefit with serelaxin. Consequently, phase 3 trials are ongoing to evaluate the effect of serelaxin and ularitide on clinical outcomes. Given the poor history of recent investigational acute HF drugs that have advanced to phase 3/4 studies, enthusiasm for both serelaxin and ularitide must be tempered until these trials are completed.